Monoclonal Antibody Research: Supply Chain Issues
John F. Kokai-Kun, PhD, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.
John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.
Dr. Kokai-Kun has shepherded several drug candidates through various phases of development, from pre-IND and IND-enabling studies, to process development, through IND submission and into early and late phase clinical studies.
The various programs which he has managed include biologic drugs; monoclonal antibodies, enzymes, peptides and vaccines; several of which have reached late stage clinical studies.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
